NCT07154992View on ClinicalTrials.gov

Clinical Trial to Evaluate the Efficacy of Lacticaseibacillus Rhamnosus CRL1505 in the Prevention of Upper Respiratory Tract Infections in Children

NARecruitingINTERVENTIONAL
Enrollment

268

Participants

Timeline

Start Date

December 17, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

April 30, 2027

Conditions
Upper Respiratory Tract InfectionPrevention
Interventions
DIETARY_SUPPLEMENT

Probiotic - Lacticaseibacillus rhamnosus CRL1505

The probiotic product is provided in 2g sticks containing the strain Lacticaseibacillus rhamnosus CRL1505 at a concentration of ≥ 1.0E+8 CFU/g, with corn starch and maltodextrin as excipients.

DIETARY_SUPPLEMENT

Placebo

The placebo product is provided in 2g sticks of corn starch and maltodextrin.

Trial Locations (1)

Unknown

RECRUITING

MiBioPath Research Group (UCAM), Murcia

Sponsors

Lead Sponsor

Bioithas SL
All Listed Sponsors
collaborator

Centro Sperimentale del Latte S.r.l.

UNKNOWN

lead

Bioithas SL

INDUSTRY

NCT07154992 - Clinical Trial to Evaluate the Efficacy of Lacticaseibacillus Rhamnosus CRL1505 in the Prevention of Upper Respiratory Tract Infections in Children | Biotech Hunter | Biotech Hunter